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ABSTRACT
This report describes the development of a real-time LightCycler assay for the detection and identification
of Candida and Aspergillus spp., using the MagNa Pure LC Instrument for automated extraction of fungal
DNA. The assay takes 5–6 h to perform. The oligonucleotide primers and probes used for species
identification were derived from the DNA sequences of the 18S rRNA genes of various fungal pathogens.
All samples were screened for Aspergillus and Candida to the genus level in the real-time PCR assay. If a
sample was Candida-positive, typing to species level was performed using five species-specific probes.
The assay detected and identified most of the clinically relevant Aspergillus and Candida spp. with a
sensitivity of 2 CFU ⁄mL blood. Amplification was 100% specific for all Aspergillus and Candida spp.
tested. To assess clinical applicability, 1650 consecutive samples (1330 blood samples, 295 samples from
other body fluids and 25 biopsy samples) from patients with suspected invasive fungal infections were
analysed. In total, 114 (6.9%) samples were PCR-positive, 5.3% for Candida and 1.7% for Aspergillus spp.
In patients with positive PCR results for Candida and Aspergillus, verification with conventional methods
was possible in 83% and 50% of cases, respectively. In conclusion, the real-time PCR assay allows
sensitive and specific detection and identification of fungal pathogens in vitro and in vivo.
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INTRODUCTION
In Sweden, Candida albicans and other Candida
spp., followed by Aspergillus spp., are the most
common fungal pathogens causing invasive fun-
gal infections (IFIs). Opportunistic IFIs are a major
cause of morbidity and mortality in immunocom-
promised patients such as transplant recipients
[1–4]. The clinical features of invasive candidiasis
are non-specific, making early diagnosis of inva-
sive candidiasis difficult [5,6]. There has been
some progress in the diagnosis of invasive asper-
gillosis (IA) in recent years, mainly because of the
use of high-resolution computerised tomography
(CT) scanning and other imaging procedures, but
established IA is difficult to treat, with a mortality
rate of 80–90% [7].
The incidence of nosocomial bloodstream infec-
tions caused by Candida spp. has increased during
the last two decades. In a recent report from
Sweden [8], the crude mortality rate of candidae-
mia was 31%. The highest mortality rates were
observed in patients with haematological malig-
nancies (41.2%), in those aged > 70 years (41%),
following surgery (38.5%), and in those infected
with more than one Candida sp. (40%) or Candida
glabrata (38%). However, blood cultures take time
andhave poor sensitivity [9–12]. As a consequence,
the diagnosis of candidaemia and aspergillosis is
generally established at a late stage, or even at
autopsy, in a considerable number of cases [13].
Non-cultural techniques used previously have
lacked sensitivity and specificity in immunocom-
promised patients [14,15]. New rapid methods
that can detect IFI early in the course of disease,
with high sensitivity and specificity, are thus
required. More recently, PCR protocols for
diagnosing fungal infections have been described
[16–22]. Molecular diagnostic methods using uni-
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versal fungal PCR primers and species-specific
probes have been developed and evaluated for
the detection of fungal DNA in clinical specimens.
Since non-albicans Candida spp. and Aspergillus
spp. are increasing in importance, it is necessary
for the fungal PCR assay to have high sensitivity
for most pathogenic Candida and Aspergillus spp.
This report describes the development of an
assay that uses a fully automated laboratory robot,
the MagNA Pure LC Instrument, for extraction of
Candida and AspergillusDNA, in combination with
the real-time PCR LightCycler System. The whole
assay takes c. 6 h to perform. To assess its clinical
applicability, a large number of blood samples,
samples from other body fluids and biopsy sam-
ples from patients with suspected IFI were ana-
lysed by the assay, and the results were compared
with those obtained by conventional methods.
MATERIALS AND METHODS
Fungal cultures
Standard fungal strains used in the study were C. albicans
ATCC 10231, C. glabrata ATCC 90030, Candida krusei ATCC
6258, Candida parapsilosis ATCC 22019, Candida tropicalis
CCUG 5570, Candida lusitaniae UKNEQAS 6208, Candida guil-
lerimondi SMI 8302, Candida norvergensis SMI 115-04, Candida
dubliniensis (sequenced), Candida kefyr SMI 7-01, Cryptococcus
neoformans ATCC 24067, Aspergillus fumigatus UKNE-
QAS 5526, Aspergillus flavus UKNEQAS 6657, Aspergillus niger
ATCC 1640, Aspergillus versicolor UKNEQAS 6406, Aspergillus
nidulans UKNEQAS 6020, Aspergillus clavatus UKNEQAS 7021,
Aspergillus glaucus UKNEQAS 5647 and Aspergillus terreus
UKNEQAS 6323. Clinical isolates were obtained from Kar-
olinska University Hospital Huddinge, Stockholm, Sweden.
Sample preparation
Before DNA extraction, Candida cultures were grown on
Sabouraud–glucose agar for 48 h at 30C, and Aspergillus
cultures were grown for 72 h at 30C. Fungal suspensions in
saline were adjusted (0.5 · MacFarland standard) to a concen-
tration of 1 · 106 to 5 · 106 cells ⁄mL. Ten-fold serial dilutions
(106)101 cells) were prepared to test the sensitivity and
specificity of the assay.
For determination of the detection limit in blood, EDTA-
anti-coagulated whole-blood samples (5 mL) from healthy
volunteers were spiked with serial dilutions of Candida and
Aspergillus (106)101 cells ⁄mL). DNA was extracted and ana-
lysed according to the protocol described below.
For specificity testing of the probes, cells from the following
yeasts and moulds were tested: Candida spp., Aspergillus spp.,
Malazessia spp., Crypt. neoformans, Saccharomyces cerevisiae,
Trichosporon spp., Fusarium spp., Zygomycetes spp., Scedospori-
um spp. and Paecilomyces spp. (Table 1).
Preparation of total genomic DNA from clinical samples
Manual steps: blood. Blood specimens (and fluids containing red
blood cells) were incubated initially with a hypotonic red cell
lysis buffer (RCLB) as described previously [19]. Following lysis
of the erythrocytes, the sample was centrifuged at 2500 g for
10 min. The pellets were transferred to 1.5-mL Eppendorf tubes
Table 1. Candida and Aspergillus spp. and additional fungal species tested by real-time PCR
Positive by hybridisation with DNA probe specific for
Common Candida
C. albicans ⁄
C. dubliniensis C. glabrata C. parapsilosis C. tropicalis C. krusei Aspergillus spp.
Candida albicans + + – + – – –
Candida glabrata + – + – – – –
Candida parapsilosis + + – + – – –
Candida tropicalis + – – – + – –
Candida krusei + – – – – + –
Candida lusitaniae + – – – – – –
Candida dubliniensis + + – + – – –
Candida kefyr + – – – – – –
Candida norvergensis + – – – – – –
Candida guillerimondi + – – – – – –
Saccharomyces cerevisiae + – – – – – –
Trichosporon spp. – – – – – – –
Malassezia spp. – – – – – – –
Cyptococcus neoformans – – – – – – –
Aspergillus fumigatus – – – – – – +
Aspergillus flavus – – – – – – +
Aspergillus niger – – – – – – +
Aspergillus versicolor – – – – – – +
Aspergillus terreus – – – – – – +
Aspergillus nidulans – – – – – – +
Aspergillus glaucus – – – – – – +
Aspergillus clavatus – – – – – – +
Zygomycetes spp. – – – – – – –
Fusarium spp. – – – – – – –
Scedosporium spp. – – – – – – –
Paecilomyces spp. – – – – – – –
Penicillium spp. – – – – – – –
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containing glass beads (1.180 lm; Sigma, Deissenhofen, Ger-
many), and vortexed thoroughly for 3 min; 200 lL of the
supernantant was then pipetted into the wells of the MagNA
Pure LC sample cartridge (Roche, Mannheim, Germany).
Manual steps: biopsies. Tissue samples were mechanically
homogenised before being suspended in 1 · RCLB (only
biopsies containing red blood cells). The mixture was then
vortexed briefly, incubated at room temperature on a rotating
platform for 10 min, and centrifuged at 13 200 g. The super-
natant was discarded and 1 mL of white cell lysis buffer [19]
was added. The tube was vortexed and incubated overnight in
a water bath at 55C, and then centrifuged for 15 min at
13 200 g. The pellet was transferred to a 1.5-mL Eppendorf
tube containing glass beads, and processed as described above.
MagNA Pure DNA isolation. DNA was extracted and purified
by the MagNA Pure DNA robot (Roche), using the MagNA
Pure LC DNA I isolation kit for all preparations. The
preparation and settings of the instrument were according to
the manufacturer’s instructions.
Primer and hybridisation probes for LightCycler-based
amplification of Candida and Aspergillus DNA
The oligonucleotide primer pair (5¢-ATTTGGAGGGCAAG-
TCTGGT and 5¢-GATCCCTAGTCGGCATAGTT), as well as
the probes described below, were designed following a
comparison of the sequences of 18S rRNA genes in the
GeneBank database. The primers target a consensus sequence
for a variety of fungal pathogens. Probes bind within the
variable areas of the gene.
The ‘common Candida’ probe was designed to detect most
pathogenic Candida spp., and comprised a ‘donor’ sequence
(5¢-CGAAAGTTAGGGGATCGAAGATG) labelled at the
5¢-end with the LightCycler Red705 fluorophore, and an
‘acceptor’ sequence (5¢-CCAAGGACGTTTTCATTAATCAAG-
A) labelled at the 3¢-end with fluorescein. Similarly, the
Candida species-specific probes were labelled at the 5¢-end of
the first (donor) sequence with the LightCycler Red640
fluorophore, and at the 3¢-end of the second (acceptor)
sequence with fluorescein. Probes used were as follows: for
C. albicans, 5¢-CGAAAGTTAGGGGATCGAAGATG and
5¢-AGCCTTTCCTTCTGGGTAGCCAT; for C. tropicalis, 5¢-GT-
CCATCTTTCTGATGCGTACTGG and 5¢-TAGTTGAACCTT-
GGGCTTGGTTGGC; for C. glabrata, 5¢-TCCTTGTGGCTT-
GGCGGCGAACCAG and 5¢-GGCCTTTCCTTCTGGCTAAC-
CCCA; for C. parapsilosis, 5¢-GACCCAGCCGAGCCTTT-
CCTTCTG and 5¢-CCGGTCCATCTTTTTTGATGCGTAC; and
for C. krusei, 5¢-CCTCGGGCGAACCAGGACGATT-3¢ and
5¢-GGCCGGGTCTTTCCTTCTGGCT.
The Aspergillus probe was designed to detect A. fumigatus,
A. flavus, A. niger, A. versicolor, A. terreus, A. nidulans,
A. glaucus and A. clavatus. The donor sequence (5¢-
TGAGGTTCCCCAGAAGGAAAGGTCCAGC) was labelled
at the 5¢-end with the LightCycler Red640 fluorophore, and
the acceptor sequence (5¢-GTTCCCCCCACAGCCAGT-
GAAGGC) was labelled at the 3¢-end with fluorescein.
All primers and probes were synthesised by Tibmolbiol
(Berlin, Germany). The primers and hybridisation probes for
Candida spp. were developed as part of the present study; the
Aspergillus probe was that described by Loeffler et al. [23].
PCR amplification and detection
The LightCycler system (Roche) was used for amplification of
Candida and Aspergillus DNA. LightCycler hot-start PCR was
performed in glass capillaries with a LightCycler Fast Start
DNA Master Hybridisation Probes kit (Roche) as specified by
the manufacturer. The PCR master mix (10 lL) contained
1 · Fast Start reaction mixture with Fast Start Taq DNA
polymerase, reaction buffer, dNTPs, 1.6 lL of 25 mM MgCl2,
1 lL of each primer (3 lM), and 1 lL (2 lM) of each hybrid-
isation probe.
PCR was performed in a final volume of 20 lL (10 lL of
master mix + 10 lL of DNA extract) with 10 min at 95C,
followed by 50 cycles of 15 s at 95C, 10 s at 58C and 20 s at
72C, with a temperature transition rate (TTR) of 20C ⁄ s. The
PCR was followed by a melting temperature analysis cycle
comprising 95C for 10 s (TTR of 20C ⁄ s), 50C for 60 s (TTR of
20C ⁄ s) and 75C for 0 s (TTR of 0.1C ⁄ s) to check the
specificity of the PCR product.
Each PCR included a negative control consisting of RCLB
without template DNA to monitor possible contamination.
Furthermore, DNA extracts from clinical samples were ana-
lysed in parallel with an extraction control and a PCR control
containing fungal DNA.
Clinical samples
All samples were screened for Aspergillus and Candida to the
genus level in the real-time PCR assay. If a sample was
positive for the Candida genus, the sample was tested further
with the Candida species-specific probes described above. The
samples analysed comprised blood (3 mL of EDTA blood from
children, 5 mL of EDTA blood from adults) and other body
fluids (in sterile tubes), as well as small biopsy samples (in
sterile saline). The samples were either analysed directly on
arrival at the laboratory, or were kept refrigerated overnight or
stored frozen during weekends before analysis.
Patients
Between 1 June 2002 and 31 October 2003, the real-time PCR
assay was used to analyse 1650 patient samples sent to the
Mycology Laboratory at Karolinska University Hospital
Huddinge from patients at risk for fungal infection, from
patients with suspicion of fungal infection, or from patients for
whom confirmation of fungal infection before, during and
after treatment was required. Classification of opportunistic
invasive fungal infections in immunocompromised patients
with cancer or haematopoietic stem-cell transplants was
according to the EORTC ⁄MSG criteria [24].
RESULTS
Combination of MagNA Pure DNA extraction
and LightCycler PCR
The in-vitro sensitivity obtained with serially
diluted genomic DNA from Candida and Aspergil-
lus spp. was 2 CFU ⁄mL blood. The hybridisation
probes for the genus Candida detected DNA from
the tenCandida spp. listed in Table 1. Identification
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to the species levelwas possiblewith the probes for
C. albicans ⁄C. dubliniensis, C. glabrata, C. parapsilo-
sis, C. tropicalis and C. krusei. The probes for
C. glabrata, C. tropicalis and C. krusei did not
cross-react with other Candida spp., but the
C. albicans ⁄C. dubliniensis probe cross-reactedwith
C. parapsilosis, and the C. parapsilosis probe cross-
reacted with C. albicans ⁄C. dubliniensis. However,
it was possible to differentiate between C. albi-
cans ⁄C. dubliniensis and C. parapsilosis following
melting curve analysis. Cross-reaction was ob-
served between the ‘common Candida probe’ and
Sacch. cerevisiae, but the species-specific Candida
probes did not cross-react with Sacch. cerevisiae.
Fungal pathogens that were negative with the
common Candida probe, the species-specific Can-
dida probes and the Aspergillus probe were Tricho-
sporon spp., Malassezia spp., Crypt. neoformans,
Zygomycetes spp., Fusarium spp., Scedosporium
spp., Paecilomyces spp. and Penicillium spp.
(Table 1).
All negative controls, consisting of RCLB or
DNA extracted from blood from healthy volun-
teers, gave negative results in LightCycler runs. A
wide range of template DNA, extracted from
various clinical isolates of non-fungal pathogens
and human cells, remained negative with the
primer pairs, as also described previously [20].
Candida and Aspergillus PCR results with
patient samples
In total, 1650 samples from 379 patients were
investigated (Table 2). Of these, 114 (6.9%) from
74 patients (1–74) were PCR-positive, comprising
86 (5.2%) from 50 patients positive for Candida
spp., and 28 (1.8%) from 24 patients positive for
Aspergillus spp. (samples from two patients were
positive for both Candida spp. and Aspergillus
spp.). Table 2 summarises the results obtained
with different types of specimens (described in
more detail below). Table 3 compares the results
obtained by PCR for the identification of Candida
to the species level with the results obtained by
conventional culture.
Characteristics of PCR-positive patients
The 74 PCR-positive patients comprised 38
females and 36 males, with a median age of
Table 2. PCR results showing Candida-positive samples (n = 86) and Aspergillus-positive samples (n = 28)
Samples No of samples
PCR-positive
Cand/Asp
Culture-positive
Cand/Asp
Culture-negative
Cand/Asp
Not done
Cand/Asp
Not known
Cand/Asp
CT-verified
Cand/Asp
BAL-positive
Cand/Asp
Other positive
tests Cand/Asp
Blood 1330 19/19 8/0 5/10 6/7 0/2 0/2b 0/Not done
BAL 89 9/7 7/3 2/4 0/2c
CSF 24 4/0 1/0a 1/0 2/0 1/0
Biopsy 25 6/0 4/0 2/0 2/0
Bile 43 31/0 23/0 1/0 7/0
Pleura 32 0/1 0/1
Abscess 50 6/0 5/0 1/0
Urine 10 3/0 2/0 1/0
Sputum 7 1/1 1/1
Tracheal secretion 6 1/0 1/0
Drainage 19 6/0 5/0 1/0
Various 15 0/0
Total 1650 86/28 57/5 12/14 17/7 0/2 3/0 0/2 0/2
aMicroscopy-positive.
bTwo cultures positive for Aspergillus spp. in bronchoalveolar lavage (BAL) fluid.
cOne microscopy- and one antibody-positive sample for Aspergillus spp.
Candida verified, 60 (83.4%) of 72; Aspergillus verified, nine (50%) of 18.
Cand, Candida; Asp, Aspergillus; CT, computerised tomography; CSF, cerebrospinal fluid.
Table 3. Candida spp. identified by
PCR, compared with results of con-
ventional culture
PCR results (n = 86) Culture results Positive = 57 Negative = 11 Not done = 18
Candida albicans 31 C. albicans 27 4
Candida tropicalis 4 C. tropicalis 4
C. albicans ⁄ tropicalis 5 C. albicans 2 2 1
C. albicans ⁄Candida parapsilosis 1 C. albicans 1
Candida glabrata 12 C. glabrata 9 3
C. glabrata ⁄Candida krusei 4 C. glabrata ⁄C. krusei 3
C. glabrata 1
C. parapsilosis 2 C. parapsilosis 1 1
C. krusei 3 C. krusei 3
Candida spp. 24 C. albicans 4 8 10
C. albicans ⁄C. tropicalis 2
Identification to the species level was possible by PCR in 62 (72%) of 86 samples.
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35 years (range 6 months to 84 years). Signifi-
cant underlying conditions were allogeneic stem
cell transplantation (SCT) (n = 27), liver trans-
plantation (n = 17), kidney transplantation
(n = 2), heart transplantation (n = 1), abdominal
surgery and treatment in an intensive care unit
(n = 5), abdominal surgery (n = 1), vascular
surgery (n = 1), treatment in an intensive care
unit (n = 3; comprising two patients with myel-
oma, and one tetrapares with pneumonia),
haematological malignancies (n = 8) and extra-
corporeal membrane oxygen treatment (n = 3);
there was also one infant with hydrocephalus
and shunt (n = 1), one neonate, and four other
patients.
Blood samples
Candida. Nineteen (1.4%) of 1330 blood samples
were PCR-positive for Candida spp. The 19 pos-
itive samples came from 18 patients, and eight
(61%) of 13 samples from seven patients (two
haematology, three abdominal surgery, one liver
transplant and one allogeneic SCT) were verified
by blood culture (Table 2; four C. albicans, two
C. parapsilosis and three C. krusei). Blood cultures
from five patients were negative (one haematol-
ogy and four allogeneic SCT), and blood cultures
were not performed for six patients (all allogeneic
SCT). In two patient samples, although the
melting curves were positive, the PCRs were
negative initially (perhaps because of inhibition
caused by excess total DNA, with 2748 ng ⁄ sam-
ple and 975 ng ⁄ sample, respectively), but were
positive following dilution of the DNA extract.
For ten patients (eight allogenic SCT, one haema-
tology and one abdominal surgery), PCR was
positive for Candida to the genus level, but was
negative with all the species-specific probes. For
the patient with abdominal surgery, identification
to the species level could not be performed
because of insufficient DNA.
Aspergillus. Nineteen (1.4%) of 1330 blood sam-
ples were PCR-positive for Aspergillus, all from 17
immunocompromised patients (Tables 2 and 4).
All blood cultures taken were negative for As-
pergillus, but the diagnosis of pulmonary asper-
gillosis could be verified by bronchoalveolar
lavage (BAL) cultures growing A. fumigatus for
two patients (61 and 66). Following X-ray, patient
6 was diagnosed with suspected necrotising
aspergillosis, while patient 8, who had a negative
X-ray at the time of the positive Aspergillus PCR
test, later developed an aircrest sign on a CT scan
of the chest that was suggestive of pulmonary
aspergillosis. No X-ray or CT scan was performed
for six patients (4, 60, 63, 64, 67 and 70), and no
data were available for six patients (35, 52, 53, 68,
69 and 71). Patient 54 had a negative X-ray at the
time of a positive Aspergillus PCR test (Table 4).
Cerebrospinal fluid samples
Four (17%) of 24 cerebrospinal fluid samples from
four patients were PCR-positive for Candida.
None were PCR-positive for Aspergillus. These
four patients comprised: an infant with hydro-
cephalus and shunt who had meningitis and was
PCR-positive for C. albicans, but culture-negative
(although cultures from cerebrospinal fluid taken
during an earlier episode had grown C. albicans);
two allogeneic SCT recipients from whom cul-
tures were not taken (one had meningitis and the
other had a fungal lesion of the brain on CT scan);
and a patient with neurological symptoms (yeast
cells were observed with direct microscopy, but
culture was negative; it was believed that
Table 4. Aspergillus PCR-positive blood samples from 17 patients
Antifungal treatment instituted:
No treatment (patients
6, 8, 52 54, 64, 70) No data (patients 53, 68)
Before positive PCR sample was taken
(patients 35, 61, 63, 66, 67, 71)
After positive PCR sample
was taken (patients 4, 60, 69)
SCT (n = 12) 4 3 5a (patient 52 died)
ALL (n = 1) 1
Cancer (n = 1) 1
Kidney transplant (n = 1) 1
Liver transplant (n = 1) 1
COPD + surgery (n = 1) 1 (patient 6 died)
aTwo patients (54 and 64) later developed suspected pulmonary aspergillosis; one patient (8) developed probable aspergillosis.
SCT, stem cell transplantation; ALL, acute lymphoblastic leukaemia; COPD, chronic obstructive pulmonary disease.
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contamination occurred at sampling, as the
patient received no antifungal treatment, but
repeated PCR, direct microscopy and culture
remained negative).
Biopsies
Six biopsy samples from three patients were
analysed. None was positive for Aspergillus by
either PCR or culture (if performed). A patient
with acute myeloid leukaemia developed chronic
disseminated candidiasis of the liver, verified by
CT scan. Two liver biopsy samples, taken 3 weeks
apart, were PCR-positive for C. albicans. A second
patient had two biopsy samples taken from the
vitreous fluid of the eye that were positive by PCR
for C. albicans, with the positive results confirmed
by cultures and direct microscopy. Finally, an
allogeneic SCT recipient had two colon biopsy
samples taken that were PCR-positive for Candida,
with the results confirmed by enrichment cultures
that grew C. albicans.
BAL samples
Candida. Nine (10%) of 89 BAL samples from
seven patients (one allogeneic SCT patient, two
intensive care unit patients, two patients who had
received extra-corporeal membrane oxygen, and
two leukaemic patients) were PCR-positive for
Candida (four C. albicans, four C. tropicalis, one
Candida sp.), with verification by culture for seven
BAL samples (Table 2).
Aspergillus. Seven (7.9%) of 89 BAL samples, taken
from seven patients (two allogeneic SCT patients,
two leukaemic patients, one patient who had
received extra-corporeal membrane oxygen, and
two other patients) were PCR-positive for Asperg-
illus, with culture verification in five patients
(Table 2). For one patient, PCR was positive with
BAL fluid from the left lung, where the patient had
an infiltrate on X-ray, but was negative on the right
side without an infiltrate. For a second patient,
PCR was negative with BAL samples, but A. fu-
migatuswas grown on culture. The two samples of
BAL fluid came from different parts of the lung.
Pleura, sputum and tracheal secretion samples
Two patient samples (one pleural fluid and one
sputum) were PCR-positive for Aspergillus, and
cultures grew A. fumigatus. One tracheal secretion
was PCR-positive for C. glabrata and C. krusei,
with C. glabrata and, some days later, C. krusei
being grown following culture.
Bile samples
Thirty-one (72%) of 43 bile samples were PCR-
positive for Candida to the genus level in 15 liver
transplant recipients. None was positive for As-
pergillus by either PCR or culture. Of the 31
samples from 12 patients that were PCR-positive
for Candida, identification to the species level was
achieved in 26 cases. The PCR results were
verified by culture in 23 of 24 samples, cultures
were not performed in seven cases, and culture
was negative for one PCR-positive patient. One
patient was PCR-positive for both C. glabrata and
C. krusei, but cultures grew only C. glabrata on
that occasion, although C. krusei was also isolated
subsequently (Table 2).
Ascites and abscess fluid samples
Of 50 samples of abscess fluid or ascites, all were
PCR-negative for Aspergillus and cultures were
negative for Aspergillus. Six (from five patients)
of the 50 samples were PCR-positive for Candida
and were also culture-positive in five cases.
Cultures were negative for all the Candida PCR-
negative samples (n = 44). One ascites sample
was PCR-positive for C. krusei, two abscess fluid
samples were positive for C. albicans, and two
were positive for C. glabrata; cultures grew
C. krusei, C. albicans and C. glabrata, respectively.
One pancreatic abscess sample was PCR-positive
for C. albicans ⁄C. tropicalis, but cultures were
negative.
Drainage samples
The 19 drainage samples were all PCR- and
culture-negative for Aspergillus, but six samples
(from three patients) were PCR-positive for Can-
dida. One patient yielded two samples that were
PCR-positive for C. albicans, with cultures grow-
ing yeast (species identification was not per-
formed). A second patient had negative cultures,
while the third yielded three samples that were
PCR-positive for C. albicans and confirmed by
culture (Table 2).
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Urine samples
Three of ten samples, from three patients, were
PCR-positive for C. albicans. Urine cultures from
two patients grew C. albicans, while a bladder
puncture sample from the third (neonate) patient
was culture-negative.
DISCUSSION
Real-time PCR has been used successfully to
diagnose infections that are difficult to detect by
conventional culture [23,25–30]. Various molecu-
lar approaches have been used for the diagnosis
of invasive aspergillosis and candidiasis, e.g.,
PCR amplification followed by restriction enzyme
analysis using species-specific probes, and nested
PCR amplification [17–20]. However, some of
these methods detect only Aspergillus spp. or
C. albicans [17], or only a few of the non-albicans
Candida spp. known to cause candidaemia [19]. A
PCR assay amplifying an 18S rRNA gene has also
been described [20].
The real-time PCR assay described in the
present study is capable of analysing blood and
other body fluids, as well as small biopsy sam-
ples, from patients with suspected IFI. The high
sensitivity of detection (2 CFU ⁄mL of blood) was
achieved by optimising the DNA extraction
method with a manual preparation step before
performing the DNA extraction with the MagNA
Pure robot, and by amplifying a gene found in
multiple (> 100) copies.
The DNA extraction method used for fungi is
crucial, since DNA extracted from different body
fluids contains not only human DNA, but
possibly also fungal, bacterial, viral and parasite
DNA. The total amount of DNA may vary greatly
from sample to sample. Inhibition may occur
when using the LightCycler probe system if the
total amount of DNA is > 500 ng ⁄ sample, and
inhibition was observed with two PCR-negative
blood samples when the melting curve analysis
showed a PCR product with the same melting
point as the Candida control. Therefore, the DNA
concentration should be measured routinely for
all samples by spectrophotometry, with dilution
of samples before PCR analysis when necessary.
In 60 (83.5%) of 72 PCR-positive samples, the
Candida PCR results were verified by culture
(78%) or other tests (5.5%). Samples that were
culture-negative, but Candida PCR-positive, were
mostly blood samples from allogeneic SCT pa-
tients, for whom blood cultures for Candida are
known to have a low sensitivity (< 50%) [9–12].
PCR was more sensitive than culture for some
patients with Candida infection verified by CT
scan (hepatosplenic and central nervous system
lesions).
Only nine (10%) of 89 BAL samples were PCR-
positive for Candida. All seven patients involved
had severe underlying diseases, and for two
patients, the PCR and cultures were positive on
two occasions each for C. tropicalis. Contamin-
ation with yeasts when performing BAL with the
technique used today seems to be unusual. The
patients with Candida PCR-positive bile samples
were all liver transplant recipients. More than one
Candida sp. could be detected in the same sample
by PCR, with the results confirmed by culture in
96% of cases, and reliable identification of the
causative Candida pathogen to species level by the
assay. Identification of Candida spp. is essential for
appropriate clinical decision-making concerning
the significance of a particular isolate and the
choice and dosage of antifungal therapy. The
specificity of the assay appeared to be high, and
detection of more than one fungal pathogen could
be achieved. Cross-reaction between the Candida
genus probe and Sacch. cerevisiae occurs, but
Sacch. cerevisiae was not isolated in any culture
from patients in the present study.
Aspergillus was detected by PCR in 28 (1.7%) of
1650 samples. Aspergillus was detected only from
blood, BAL, pleura and sputum. In all other
samples, PCR and cultures (when taken) were
negative for Aspergillus. For BAL, pleura and
sputum samples, the PCR result was verified in
seven (78%) of nine cases. It is well-known that
blood cultures are often negative in patients with
proven aspergillosis, and it was therefore not
possible to compare the PCR-positive results for
Aspergillus with blood cultures. Interestingly,
positive PCR results for Aspergillus with blood
were found only with blood from 17 severely
immunocompromised patients at high risk for IA
(Table 4). Of these patients, six were receiving
antifungal prophylaxis and three had received
early treatment. Five patients did not receive any
antifungal treatment; of these, two died, two
developed suspected pulmonary aspergillosis,
and one developed probable aspergillosis. No
data were available for two patients. The final
patient (70), a child who was an allogeneic SCT
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recipient and had engraftment at the same time as
the PCR was positive for Aspergillus, did not
develop clinical symptoms of IA despite an
absence of antifungal treatment (Table 4).
Construction work in the vicinity is a known
risk-factor for IA in immunosuppressed individ-
uals because of the possible exposure to Asperg-
illus spores [31]. During the 17-month study
period, 11 allogeneic SCT patients were hospital-
ised at Karolinska University Hospital Huddinge.
During the first 5 months, only one patient was
PCR-positive for Aspergillus in blood. During the
following 6 months, extensive construction work
took place in the vicinity of the SCT ward, and
blood samples for seven patients were PCR-
positive for Aspergillus. During the subsequent
6-month period, with no construction near the
ward, three patients were PCR-positive.
DNA may have been detected at an early stage
of infection in some patients, i.e., before clinical
signs of disease. ‘Infection’ and ‘disease’ might
not be synonymous when DNA detection is used
for screening. The pathogenesis of IA is poorly
understood. Spores are inhaled and may form
hyphae when deposited in the alveoli of the
lungs. Fungal DNA (spores and ⁄ or hyphae) may
be released into the bloodstream at this stage,
with clinical signs (e.g., patients 6, 61 and 66), but
also without real evidence of disease (e.g., patient
8), which does not equate to an absence of disease;
indeed, patient 8 later developed aircrest signs on
CT scan that were suggestive of pulmonary
aspergillosis (Table 4). The spread of Aspergillus
through the bloodstream to internal organs may
take place long before the patient develops clin-
ical symptoms.
The goal of diagnostic research in invasive
mycoses should be to detect the presence of the
fungus as early as possible. With a rapid and
highly sensitive assay, such as a real-time PCR, it
may be possible to identify infected patients at an
early stage. If so, real-time PCR may be useful
also for excluding patients at risk; thus, the
negative predictive value might be of great
importance.
In conclusion, the real-time PCR assay described
in this study provides high sensitivity and specif-
icity for the detection of fungal DNA in blood,
various body fluids and biopsy sampleswithin 6 h,
and identifies most Candida spp. Further clinical
studies are needed to elucidate the true potential of
such new techniques for different patient groups.
There is a need for prospective studies to evaluate
the potential benefits of early therapy, based on
real-time PCR, in patients at risk for invasive
Candida and Aspergillus infection.
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